Oncocyte Corp Quarterly Operating Income (Loss) in USD from Q1 2015 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Oncocyte Corp quarterly/annual Operating Income (Loss) history and growth rate from Q1 2015 to Q2 2024.
  • Oncocyte Corp Operating Income (Loss) for the quarter ending June 30, 2024 was -$4.63M, a 44.2% increase year-over-year.
  • Oncocyte Corp Operating Income (Loss) for the twelve months ending June 30, 2024 was -$36.6M, a 132% decline year-over-year.
  • Oncocyte Corp annual Operating Income (Loss) for 2023 was -$25.1M, a 39.7% decline from 2022.
  • Oncocyte Corp annual Operating Income (Loss) for 2022 was -$18M, a 66.5% increase from 2021.
  • Oncocyte Corp annual Operating Income (Loss) for 2021 was -$53.7M, a 80.8% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 -$36.6M -$4.63M +$3.66M +44.2% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-08
Q1 2024 -$40.3M -$9.27M -$15.1M -258% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-15
Q4 2023 -$25.1M -$16.2M -$4.53M -38.9% Oct 1, 2023 Dec 31, 2023 10-K 2024-04-16
Q3 2023 -$20.6M -$6.51M -$4.81M -282% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-09
Q2 2023 -$15.8M -$8.29M -$6.67M -410% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-08
Q1 2023 -$9.13M $5.85M +$8.87M Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-15
Q4 2022 -$18M -$11.6M +$24M +67.4% Oct 1, 2022 Dec 31, 2022 10-K 2024-04-16
Q3 2022 -$42M -$1.71M +$11.9M +87.5% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 -$53.9M -$1.63M +$11.9M +88% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-10
Q1 2022 -$65.9M -$3.02M +$8.34M +73.4% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-15
Q4 2021 -$74.2M -$35.7M -$29.4M -469% Oct 1, 2021 Dec 31, 2021 10-K 2022-03-11
Q3 2021 -$44.8M -$13.6M -$7.36M -118% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-10
Q2 2021 -$37.4M -$13.6M -$4.8M -54.7% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-12
Q1 2021 -$32.6M -$11.4M -$2.93M -34.7% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-12
Q4 2020 -$29.7M -$6.27M +$1.26M +16.7% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-11
Q3 2020 -$31M -$6.24M -$987K -18.8% Jul 1, 2020 Sep 30, 2020 10-K 2022-03-11
Q2 2020 -$30M -$8.77M -$3.31M -60.5% Apr 1, 2020 Jun 30, 2020 10-K 2022-03-11
Q1 2020 -$26.7M -$8.43M -$4.43M -111% Jan 1, 2020 Mar 31, 2020 10-K 2022-03-11
Q4 2019 -$22.2M -$7.52M -$3.48M -85.9% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-19
Q3 2019 -$18.8M -$5.26M -$2.23M -73.9% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-12
Q2 2019 -$16.5M -$5.46M -$1.24M -29.2% Apr 1, 2019 Jun 30, 2019 10-Q 2020-07-29
Q1 2019 -$15.3M -$4M -$91K -2.33% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-12
Q4 2018 -$15.2M -$4.05M -$154K -3.96% Oct 1, 2018 Dec 31, 2018 10-K 2020-03-26
Q3 2018 -$15M -$3.02M +$3.81M +55.8% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-14
Q2 2018 -$18.9M -$4.23M -$637K -17.7% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-14
Q1 2018 -$18.2M -$3.91M +$626K +13.8% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-14
Q4 2017 -$18.8M -$3.89M -$799K -25.8% Oct 1, 2017 Dec 31, 2017 10-K 2019-04-01
Q3 2017 -$18.1M -$6.84M -$4.25M -165% Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-13
Q2 2017 -$13.8M -$3.59M -$1.06M -41.7% Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-14
Q1 2017 -$12.7M -$4.53M -$1.6M -54.6% Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-15
Q4 2016 -$11.1M -$3.09M +$446K +12.6% Oct 1, 2016 Dec 31, 2016 10-K 2018-04-02
Q3 2016 -$11.6M -$2.58M -$176K -7.32% Jul 1, 2016 Sep 30, 2016 10-Q 2017-11-14
Q2 2016 -$11.4M -$2.53M -$1.13M -80.2% Apr 1, 2016 Jun 30, 2016 10-Q 2017-08-14
Q1 2016 -$10.3M -$2.93M -$1.57M -114% Jan 1, 2016 Mar 31, 2016 10-Q 2017-04-28
Q4 2015 -$8.72M -$3.54M Oct 1, 2015 Dec 31, 2015 10-K 2018-04-02
Q3 2015 -$2.41M Jul 1, 2015 Sep 30, 2015 10-Q 2016-11-10
Q2 2015 -$1.41M Apr 1, 2015 Jun 30, 2015 10-Q 2016-08-11
Q1 2015 -$1.37M Jan 1, 2015 Mar 31, 2015 10-Q 2016-05-16
* An asterisk sign (*) next to the value indicates that the value is likely invalid.